Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig

Lei, Changhai; Fu, Wenyan; Qian, Kunxi; Tian, Li; Zhang, Sheng; Ding, Min; Hu, Shi

doi:10.1101/2020.02.01.929976

Cited by 93 publications

(97 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although there are four amino acid variations of S protein between 2019-nCoV and SARS-CoV, 2019-nCoV can also bind to the human angiotensinconverting enzyme 2 (ACE2), the same host receptor for SARS-CoV, as 2019-nCoV can bind to the ACE2 receptor from the cells from human, bat, civet cat, and pig, but it cannot bind to the cells without ACE2 11,[33][34][35] . A recombinant ACE2-Ig antibody, a SARS-CoV-specific human monoclonal antibody, and the serum from a convalescent SARS-CoV-infected patient, which can neutralize 2019-nCoV, confirmed ACE2 as the host receptor for 2019-nCoV [36][37][38][39] . The high affinity between ACE2 and 2019-nCoV S protein also suggested that the population with higher expression of ACE2 might be more susceptible to 2019-nCoV 40,41 .…”

Section: Characteristics Of 2019 Novel Coronavirusmentioning

confidence: 89%

Transmission routes of 2019-nCoV and controls in dental practice

et al. 2020

View full text Add to dashboard Cite

A novel β-coronavirus (2019-nCoV) caused severe and even fetal pneumonia explored in a seafood market of Wuhan city, Hubei province, China, and rapidly spread to other provinces of China and other countries. The 2019-nCoV was different from SARS-CoV, but shared the same host receptor the human angiotensin-converting enzyme 2 (ACE2). The natural host of 2019-nCoV may be the bat Rhinolophus affinis as 2019-nCoV showed 96.2% of whole-genome identity to BatCoV RaTG13. The person-to-person transmission routes of 2019-nCoV included direct transmission, such as cough, sneeze, droplet inhalation transmission, and contact transmission, such as the contact with oral, nasal, and eye mucous membranes. 2019-nCoV can also be transmitted through the saliva, and the fetal–oral routes may also be a potential person-to-person transmission route. The participants in dental practice expose to tremendous risk of 2019-nCoV infection due to the face-to-face communication and the exposure to saliva, blood, and other body fluids, and the handling of sharp instruments. Dental professionals play great roles in preventing the transmission of 2019-nCoV. Here we recommend the infection control measures during dental practice to block the person-to-person transmission routes in dental clinics and hospitals.

show abstract

Section: Characteristics Of 2019 Novel Coronavirusmentioning

confidence: 89%

Transmission routes of 2019-nCoV and controls in dental practice

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Synthetic antibodies represent an exciting, novel therapeutic avenue. One strategy being explored is to fuse ACE2 to Fc IgG, with the hypothesis that this synthetic antibody would serve as a decoy receptor, preventing cellular binding of the virion (143).…”

Section: Neutralizing Antibodies and Decoy Proteinsmentioning

confidence: 99%

COVID-19 for the Cardiologist

Atri

Siddiqi

Lang

et al. 2020

JACC: Basic to Translational Science

270

137

View full text Add to dashboard Cite

Highlights-Severe acute respiratory virus-2 (SARS-CoV2), the infection responsible for coronavirus disease-2019 (COVID-19), has spread globally leading to a devastating loss of life. In a few short months, the clinical and scientific communities have rallied to rapidly evolve our understanding of the mechanism(s) of disease and potential therapeutics. -This review discusses the current understanding of the basis virology of SARS-CoV2 and the epidemiology, clinical manifestations, including cardiovascular, and mortality of COVID-19. A detailed review of the viral life cycle and putative mechanism(s) of injury frames the discussion of possible preventative and therapeutic strategies. -The ongoing, unprecedented collective effort will, without a doubt, advance our ability to prevent the spread and optimally care for patients suffering from COVID-19. SummaryThe coronavirus disease-2019 (COVID-19), a contagious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV2), has reached pandemic status. As it spreads across the world, it has overwhelmed healthcare systems, strangled the global economy and led to a devastating loss of life. Widespread efforts from regulators, clinicians and scientists are driving a rapid expansion of knowledge of the SARS-CoV2 virus and the COVID-19 disease.We review the most current data with a focus on our basic understanding of the mechanism(s) of disease and translation to the clinical syndrome and potential therapeutics. We discuss the basic virology, epidemiology, clinical manifestation, multi-organ consequences, and outcomes. With a focus on cardiovascular complications, we propose several mechanisms of injury. The virology and potential mechanism of injury form the basis for a discussion of potential disease-modifying therapies.

show abstract

“…The genome sequence of SARS-CoV-2 is 82% identical to SARS-CoV [4]. Angiotensin converting enzyme II (ACE2) was identified as the cell entry receptor of SARS-CoV-2 to infect human, similar to SARS-CoV [6]. ACE2 belongs to the angiotensin-converting enzyme family and catalyzes the cleavage of angiotensin II into the vasodilator angiotensin 1-7.…”

Section: Introductionmentioning

confidence: 99%

EZH2-mediated H3K27me3 inhibits ACE2 expression

Zhou

2020

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

Available online xxx Keywords: Coronavirus SARS-CoV-2 ACE2 EZH2 H3.3 a b s t r a c tThe outbreak of corona virus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is spreading globally and quickly, leading to emerging health issues. SARS-CoV-2 enters into and infects host cells through its spike glycoprotein recognizing the cell receptor Angiotensin-converting enzyme II (ACE2).Here, we noticed that ACE2 was further enhanced by SARS-CoV-2 infection. Human germ cells and early embryos express high level of ACE2. Notably, RNA-seq result showed that reduction of H3K27me3, but not H3K4/9/36me3, led to upregulation of Ace2 expression in mouse germ cell line GC-2. In agreement with this result, we found in human embryonic stem cells that ACE2 expression was significantly increased in absence of EZH2, the major enzyme catalyzing H3K27me3. ChIP-seq analysis further confirmed decrease of H3K27me3 signal and increase of H3K27ac signal at ACE2 promoter upon EZH2 knockout. Therefore, we propose that EZH2-mediated H3K27me3 at ACE2 promoter region inhibits ACE2 expression in mammalian cells. This regulatory pattern may also exist in other human cells and tissues. Our discovery provides clues for pathogenesis and targeted drug therapy towards ACE2 expression for prevention and adjuvant therapy of COVID-19.

show abstract

Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig

Cited by 93 publications

References 26 publications

Transmission routes of 2019-nCoV and controls in dental practice

Transmission routes of 2019-nCoV and controls in dental practice

COVID-19 for the Cardiologist

EZH2-mediated H3K27me3 inhibits ACE2 expression

Contact Info

Product

Resources

About